Episurf Medical is planning the 500th surgery with the Episealer® implant, which will occur in Germany.
Episealer devices treat localized cartilage damage in the knee. The implants and associated surgical tools are approved under the CE Mark. At the end of 2018, the company announced FDA approval for its Investigational Device Exemption application to initiate a clinical trial of the Episealer knee implant; the two-year prospective, randomized, controlled, multi-center study will evaluate the device vs. microfracture in the treatment of focal femoral knee chondral or osteochondral lesions in 180 patients in the U.S. and Europe.
“Reaching this milestone while we are experiencing a continuous flow of successful patient outcomes is of great importance to us. Our customers are constantly talking to us about the challenge in treating the middle-aged patients who suffer from early cartilage and bone lesions in the knee joint. It is our vision to help these patients to return to a normal lifestyle, and we are very determined on delivering on this vision,” says Pål Ryfors, CEO Episurf Medical.
Episurf Medical is planning the 500th surgery with the Episealer® implant, which will occur in Germany.
Episealer devices treat localized cartilage damage in the knee. The implants and associated surgical tools are approved under the CE Mark. At the end of 2018, the company announced FDA approval for its Investigational Device Exemption...
Episurf Medical is planning the 500th surgery with the Episealer® implant, which will occur in Germany.
Episealer devices treat localized cartilage damage in the knee. The implants and associated surgical tools are approved under the CE Mark. At the end of 2018, the company announced FDA approval for its Investigational Device Exemption application to initiate a clinical trial of the Episealer knee implant; the two-year prospective, randomized, controlled, multi-center study will evaluate the device vs. microfracture in the treatment of focal femoral knee chondral or osteochondral lesions in 180 patients in the U.S. and Europe.
“Reaching this milestone while we are experiencing a continuous flow of successful patient outcomes is of great importance to us. Our customers are constantly talking to us about the challenge in treating the middle-aged patients who suffer from early cartilage and bone lesions in the knee joint. It is our vision to help these patients to return to a normal lifestyle, and we are very determined on delivering on this vision,” says Pål Ryfors, CEO Episurf Medical.
Copy to clipboard 
